Orchestra BioMed Holdings, Inc. is a biomedical innovation company. The Company’s lead product candidates include Atrioventricular Interval Modulation (AVIM) therapy for the treatment of hypertension (HTN), the leading risk factor for death worldwide and the Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. The Company develops bioelectronic therapies based on patented Cardiac Neuromodulation Therapy (CNT) technology. The AVIM is a bioelectronic therapy candidate designed to substantially and persistently lower blood pressure. Its Virtue SAB is a proprietary drug/device combination product candidate for the treatment of artery disease that is designed to deliver a proprietary, investigational, extended-release formulation of sirolimus (SirolimusEFR) to the vessel wall during balloon angioplasty without the need for balloon coating or a permanent implant.
Código da empresaOBIO
Nome da EmpresaOrchestra Biomed Holdings Inc
Data de listagemAug 04, 2020
CEOHochman (David P)
Número de funcionários70
Tipo de títulosOrdinary Share
Fim do ano fiscalAug 04
Endereço150 Union Square Drive
CidadeNEW HOPE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal18938
Telefone16463439298
Site
Código da empresaOBIO
Data de listagemAug 04, 2020
CEOHochman (David P)
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.

Sem dados